Sawa T, Kinoshita K, Takekawa S, Ohyama S, Hasegawa K, Fujimura T, Ueda N, Watanabe T, Kato M, Miyata T
Dept. of Surg., National Sanatorium Tsuruga Hospital.
Gan To Kagaku Ryoho. 1990 Dec;17(12):2381-6.
CDDP, MMC, UFT and Etoposide (PMUE)-combined therapy was applied to 60 cases of terminal gastric cancer to examine its effectiveness. PMUE therapy consists of i.v. injection of CDDP 75 mg/body and MMC 10 mg/body on day 1, i.v. injection of Etoposide 50 mg/body on days 3, 4 and 5 and consecutive daily administration of UFT 400 mg/body, with 3 weeks as one course. Of 42 cases having estimable lesions, 23 (53.8%) showed high rate of effectiveness (PR). Especially, of 23 cases receiving no previous treatment, 15 (65.2%) benefitted by the therapy (PR) and 9 (69.2%) of 13 non-resected cases, to a wonderful extent. Five non-resected cases showed such a reduction in tumor size as made gastrectomy possible. As for the prognosis, one year-survival rate was 34.3, 49.0 and 16.0% for all 42 cases, 23 effective cases and 19 ineffective cases, respectively, with significant (p less than 0.001) prognostic prolongation for effective cases compared with ineffective ones. Side effects were digestive symptoms (85.7%), epilation (81.0%) and myelopathy (73.8%), which were all transitory and recovered. The present PMUE therapy was regarded as one of the best combined chemotherapies for terminal gastric cancer.
对60例晚期胃癌患者采用顺铂（CDDP）、丝裂霉素（MMC）、优福定（UFT）和依托泊苷（PMUE）联合疗法，以检验其疗效。PMUE疗法包括在第1天静脉注射CDDP 75mg/体和MMC 10mg/体，在第3、4、5天静脉注射依托泊苷50mg/体，连续每日给予UFT 400mg/体，3周为一个疗程。在42例有可评估病变的患者中，23例（53.8%）显示出高有效率（PR）。特别是，在23例未接受过先前治疗的患者中，15例（65.2%）从该疗法中获益（PR），在13例未切除的病例中有9例（69.2%）在很大程度上获益。5例未切除的病例肿瘤大小缩小到可行胃切除术的程度。至于预后，42例全部患者、23例有效患者和19例无效患者的1年生存率分别为34.3%、49.0%和16.0%，有效患者与无效患者相比预后显著延长（p<0.001）。副作用为消化系统症状（85.7%）、脱发（81.0%）和骨髓病（73.8%），均为暂时性且可恢复。目前的PMUE疗法被认为是晚期胃癌最佳联合化疗方法之一。
